Ascendia

  MARKET NEWS

PCI
iDEL Therapeutics Partners with Daiichi Sankyo to Evaluate Novel Cancer Drug Delivery Platform
Daewoong Group Advances Two Drug Delivery Platforms Targeting Injectable Biologics and Microneedle Applications
Eye Drop Candidate Targets Multiple Pathways in Diabetic Macular Edema
GT Biopharma Explores KRAS Inhibitor Combination Following Positive Pancreatic Cancer Study Results
SK Biopharmaceuticals Launches U.S. Market Entry Platform for Korean Life Sciences Companies
Microneedle Biosensors Show Potential for Real-Time, Minimally Invasive Diagnostics
Abbott and Novo Expand Semaglutide Partnership Across Asia Pacific With New Brand Launch
MediPharm Labs Clears European Regulatory Hurdle for Metered-Dose Cannabis Inhaler
Thermo Fisher Introduces Compact Imaging System for Protein and Nucleic Acid Gels
Dipharma Enters UK Market Through Acquisition of Rare Disease Pharmaceutical Partner
T-Therapeutics Secures $133M to Advance Cancer and Autoimmune Disease Therapies Into Clinical Trials
AstraZeneca Eyes $10B Rhythm Pharmaceuticals Acquisition to Expand Rare Disease Portfolio
Shilpa CDMO Invests $50 Million to Expand Peptide Manufacturing Capacity in India
Emvena Therapeutics Launches With Funding to Develop Placenta-Targeted Preeclampsia Treatment
Phillips Medisize Expands UK Inhalation Operations With Chippenham Site Acquisition

  EXPERT CONTENT & RESOURCES

Lonza
CASE STUDY - Accelerating Tablet Technology Transfer Using Compaction Simulation

CASE STUDY - Accelerating Tablet Technology Transfer Using Compaction Simulation

This case study describes how compaction simulation allowed our customer to investigate the causes of tabletability loss during dry granulation and confirm the potential impact of over-lubrication during scale-up. The results established a defined processing window for roller compaction and tableting, enabling the team to de-risk technology transfer, conserve material, and support efficient scale-up.

Cecilia Xi, VP of Clinical and Scientific Affairs at Vivalink

INTERVIEW - From Data Collection to Data Provenance: Building More Traceable Infrastructure for Decentralized Trials

Cecilia Xi, VP of Clinical and Scientific Affairs at Vivalink, explains why data provenance, vendor oversight, and long-term governance matter more than data collection as decentralized trials scale.

Industry Education: Credence MedSystems - Insights on Solving Injectable Drug Delivery Challenges

Industry Education: Credence MedSystems - Insights on Solving Injectable Drug Delivery Challenges

As injectable therapies evolve, so do the challenges of delivering them. Credence MedSystems has launched the Industry Education home on our website where we share practical perspectives on important topics in injectable drug delivery, including larger-volume prefilled syringes, precision intravitreal dosing, dual chamber delivery and other emerging drug delivery challenges.

  FEATURED EDITORIAL

  EXPERT INSIGHTS VIDEOS

The Future of Excipients in Drug Development: AI, Lipids & Next-Generation Formulation Strategies

The Future of Excipients in Drug Development: AI, Lipids & Next-Generation Formulation Strategies

  COMPANY PROFILE

Vetter produces aseptically prefilled syringes, cartridges, vials and dual-chamber systems as a globally operating CDMO partner. We are a reliable, family-owned, independent company rooted in 75+ years of history. We do not manufacture our own drugs. We support our customers from the initial phases of clinical drug product development and filling to commercial manufacturing, device assembly and packaging, and lifecycle management. Over 80% of our active projects are biologics.

Our portfolio of services includes dedicated resources for drug product development, aseptic filling and visual inspection, device assembly and packaging, recently expanded analytical services, regulatory support and logistic services. We provide tailored solutions to meet your product’s specific market needs.

Learn More

  WHITEPAPERS & WEBINARS

H&T Presspart
WEBINAR - Primary Packaging for Sensitive Biologic Injectables: A Cross-Functional Discussion Between UCB and Aptar Pharma

WEBINAR - Primary Packaging for Sensitive Biologic Injectables: A Cross-Functional Discussion Between UCB and Aptar Pharma

Aptar Pharma and UCB discuss primary packaging for sensitive biologic injectables, covering component selection, contaminants such as silicone and tungsten, and the cross-functional decisions that protect product integrity and patient safety.

WEBINAR - Revolutionize API formulation with AEROPERL® 300 Pharma – Unlocking solubility challenges

WEBINAR - Revolutionize API formulation with AEROPERL® 300 Pharma – Unlocking solubility challenges

Poor aqueous solubility is a key barrier for a growing share of new drug candidates, limiting their bioavailability and development potential. Evonik’s AEROPERL® 300 Pharma excipient helps formulators improve the solubility and bioavailability of poorly water-soluble APIs. Join presenter Carolina Mathias, Senior Applied Technical Manager at Evonik Smart Effects, on Thursday, November 26 at 9:00 a.m. CET for first-hand formulation guidance.

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

November 18 – Controlled Release
November 25 – Bioavailability
December 2 – Inhalation Drug Delivery
December 9 – ODT/Fast Dissolve

To advertise in a future eNewsletter contact:

John Kiesewetter jkiesewetter@drug-dev.com
Amy Nicklaus anicklaus@drug-dev.com

Submit eNewsletter content:

Cindy Dubin cdubin@drug-dev.com
Ralph Vitaro rvitaro@drug-dev.com